These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38320689)

  • 1. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; Lock RB
    Exp Hematol; 2024 Apr; 132():104176. PubMed ID: 38320689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
    Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
    Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
    Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
    Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.
    Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H
    Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
    Machida M; Fukunaga S; Hara T
    Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
    Maletzke S; Salimi A; Vieri M; Schroeder KM; Schemionek M; Masouleh BK; Brümmendorf TH; Koschmieder S; Appelmann I
    PLoS One; 2022; 17(10):e0268352. PubMed ID: 36194587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
    Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
    Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
    Evans K; Duan J; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB
    Clin Cancer Res; 2019 Jul; 25(14):4493-4503. PubMed ID: 31015346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
    Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
    Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population.
    Karalis JD; Yoon LY; Hammer STG; Hong C; Zhu M; Nassour I; Ju MR; Xiao S; Castro-Dubon EC; Agrawal D; Suarez J; Reznik SI; Mansour JC; Polanco PM; Yopp AC; Zeh HJ; Hwang TH; Zhu H; Porembka MR; Wang SC
    J Transl Med; 2022 Mar; 20(1):116. PubMed ID: 35255940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixazomib in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.
    Woiterski J; Ebinger M; Witte KE; Goecke B; Heininger V; Philippek M; Bonin M; Schrauder A; Röttgers S; Herr W; Lang P; Handgretinger R; Hartwig UF; André MC
    Int J Cancer; 2013 Oct; 133(7):1547-56. PubMed ID: 23526331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI.
    Zhu Y; Ramasawmy R; Johnson SP; Taylor V; Gibb A; Pedley RB; Chattopadhyay N; Lythgoe MF; Golay X; Bradley D; Walker-Samuel S
    Sci Rep; 2018 Oct; 8(1):15068. PubMed ID: 30305717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphologic and Immunohistochemical Characterization of Spontaneous Lymphoma/Leukemia in NSG Mice.
    Tillman H; Janke LJ; Funk A; Vogel P; Rehg JE
    Vet Pathol; 2020 Jan; 57(1):160-171. PubMed ID: 31736441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.